Journal ArticleOPEN ACCESS

AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis

  • Teleman D
  • Chung C
  • Ayala A
  • et al.
Critical Care (2011) 15(S3)
DOI: 10.1186/cc10404
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

AB103 is a novel CD28 antagonist peptide currently in clinical development that modulates CD28 signaling in T cells, without affecting the normal humoral immune response. In experimental models of Gram-positive, Gram-negative and polymicrobial sepsis, AB103 demonstrated significant activity, increasing overall survival.

Cite

CITATION STYLE

APA

Teleman, D., Chung, C.-S., Ayala, A., Opal, S., Chahin, A., & Shirvan, A. (2011). AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Critical Care, 15(S3). https://doi.org/10.1186/cc10404

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free